

1       ginning with 2020), such payment amounts for a  
2       month shall be made on the first business day occur-  
3       ring on or after the following date for that month:

4               “(A) For the month of January, January  
5       2nd.

6               “(B) For the month of February, Feb-  
7       ruary 5th.

8               “(C) For the month of March, March  
9       10th.

10              “(D) For the month of April, April 15th.

11              “(E) For the month of May, May 20th.

12              “(F) For the month of June, June 25th.

13              “(G) For the month of July and each suc-  
14       ceeding month (other than December) in a  
15       year, the first day of the next month.

16              “(H) For the month of December, Decem-  
17       ber 24th.”.

## 18   **Subtitle B—Cures Innovation Fund**

### 19   **SEC. 4041. CURES INNOVATION FUND.**

20       (a) ESTABLISHMENT.—There is hereby established in  
21       the Treasury of the United States a fund to be known  
22       as the Cures Innovation Fund (in this section referred to  
23       as the “Fund”).

24       (b) APPROPRIATIONS.—There is hereby appropriated  
25       to the Fund, out of any funds in the Treasury not other-

1 wise appropriated, \$110,000,000 for each of fiscal years  
2 2016 through 2020.

3 (c) EXPENDITURES.—Amounts in the Fund shall be  
4 available, as provided by appropriation Acts, for making  
5 expenditures for carrying out the following:

6 (1) Section 229A of the Public Health Service  
7 Act, as added by section 1123 (relating to data on  
8 natural history of diseases).

9 (2) Part E of title II of the Public Health Serv-  
10 ice Act, as added by section 1141 (relating to Coun-  
11 cil for 21st Century Cures).

12 (3) Section 2001 and the amendments made by  
13 such section (relating to development and use of pa-  
14 tient experience data to enhance structured risk ben-  
15 efit assessment framework).

16 (4) Section 2021 and the amendments made by  
17 such section (relating to qualification of drug devel-  
18 opment tools).

19 (5) Section 2062 and the amendments made by  
20 such section (relating to utilizing evidence from clin-  
21 ical experience).

22 (6) Section 2161 (relating to grants for study-  
23 ing the process of continuous drug manufacturing).

1 (c) SUPPLEMENT, NOT SUPPLANT; PROHIBITION  
2 AGAINST TRANSFER.—Funds appropriated by subsection

3 (b)—

4 (1) shall be used to supplement, not supplant,  
5 amounts otherwise made available to the National  
6 Institutes of Health and the Food and Drug Admin-  
7 istration; and

8 (2) notwithstanding any transfer authority in  
9 any appropriation Act, shall not be used for any  
10 purpose other than the expenditures listed in sub-  
11 section (c).

## 12 **Subtitle C—Other Reforms**

### 13 **SEC. 4061. SPR DRAWDOWN.**

14 (a) DRAWDOWN AND SALE.—Notwithstanding sec-  
15 tion 161 of the Energy Policy and Conservation Act (42  
16 U.S.C. 6241), the Secretary of Energy shall draw down  
17 and sell 8,000,000 barrels of crude oil from the Strategic  
18 Petroleum Reserve during each of the fiscal years 2018  
19 through 2025, except as provided in subsection (b).

20 Amounts received for a sale under this subsection shall  
21 be deposited in the General Fund of the Treasury during  
22 the fiscal year in which the sale occurs.

23 (b) EMERGENCY PROTECTION.—The Secretary shall  
24 not draw down and sell crude oil under this section in  
25 amounts that would result in a Strategic Petroleum Re-